Oncolytics Biotech® Inc. Announces Pricing of Common Share Offering

Oncolytics Biotech® Inc. Announces Pricing of Common Share Offering 
CALGARY, Feb. 20, 2013 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics") 
(TSX:ONC; NASDAQ:ONCY) announced today the pricing of an underwritten public 
offering of 8.0 million common shares, at a public offering price of US$4.00 
per common share. The Company estimates that the gross proceeds from the 
offering, before deducting underwriting discounts and commissions and other 
estimated offering expenses payable by Oncolytics, will be US$32.0 million. 
The offering is expected to close on or about February 25, 2013, subject to 
customary closing conditions. 
Piper Jaffray & Co. and Wedbush PacGrow Life Sciences are acting as joint 
book-running managers for the offering in the U.S. and Paradigm Capital Inc. 
is acting as co-manager in the U.S. and book-running manager in Canada. 
The Company has granted to the underwriters participating in the offering a 
30-day option to purchase up to an additional 1.2 million common shares to 
cover over-allotments, if any. 
Oncolytics intends to use the net proceeds from the offering to fund its 
clinical trial program, manufacturing program and for general corporate and 
working capital purposes. 
The common shares are being offered in each of the Canadian provinces of 
British Columbia, Alberta, Manitoba and Ontario by way of a prospectus 
supplement to the Company's base shelf short form prospectus and in the United 
States pursuant to a prospectus supplement to the Company's effective shelf 
registration statement on Form F-10 (333-182260) previously filed with the 
United States Securities and Exchange Commission. Copies of the prospectus 
supplement and accompanying base prospectus relating to the offering may be 
obtained from the Securities and Exchange Commission website at 
http://www.sec.gov, from the System for Electronic Document Analysis and 
Retrieval (SEDAR) website at http://www.sedar.com or from the underwriters at: 
Piper Jaffray & Co.
800 Nicollet Mall, J12S03, Minneapolis, MN 55402
Email: prospectus@pjc.com
Telephone: (800) 747-3924 
Wedbush Securities Inc.
One Bush Street, 17th floor, San Francisco, CA 94104
Attn: SF Prospectus Department
Phone: 415-274-6819
Fax: 415-274-6887 
Before you invest, you should read the prospectus supplement and accompanying 
prospectus, the registration statement, and the other documents that the 
Company has filed with the Securities and Exchange Commission for more 
complete information about the Company and this offering. 
This press release does not and shall not constitute an offer to sell or the 
solicitation of an offer to buy any of the securities, nor shall there be any 
sale of the securities in any state or jurisdiction in which such offer, 
solicitation or sale would be unlawful prior to registration of qualification 
under the securities laws of any state or jurisdiction. 
About Oncolytics Biotech Inc. 
Oncolytics is a Calgary-based biotechnology company focused on the development 
of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical 
program includes a variety of human trials including a Phase III trial in head 
and neck cancers using REOLYSIN(®), its proprietary formulation of the human 
reovirus. 
This press release contains forward-looking statements within the meaning of 
the U.S. Securities Act of 1933, as amended, and U.S. Securities Exchange Act 
of 1934, as amended, and forward-looking information within the meaning of 
Canadian securities laws. Statements, other than statements of historical 
facts, included in this press release that address activities, events or 
developments that Oncolytics expects or anticipates will or may occur in the 
future, including such things as the closing of offering of common shares and 
the intended use of proceeds and other such matters are forward-looking 
statements and forward-looking information and involve known and unknown risks 
and uncertainties, which could cause the Company's actual results to differ 
materially from those in the forward-looking statements and forward-looking 
information. Such risks and uncertainties include, among others, risks related 
to the closing conditions of the offering and risks related to the Company's 
business which may result in the intended use of proceeds changing. Investors 
should consult the Company's quarterly and annual filings with the Canadian 
and U.S. securities commissions for additional information on risks and 
uncertainties relating to the forward-looking statement and forward-looking 
information. Investors are cautioned against placing undue reliance on 
forward-looking statements and forward-looking information. The Company does 
not undertake to update these forward-looking statements and forward-looking 
information, except as required by applicable laws. 
 
Oncolytics Biotech Kirk Look 210, 1167 Kensington Cr NW Calgary, Alberta T2N 
1X7 Tel: 403.670.7377 Fax: 403.283.0858 klook@oncolytics.ca  The Equicom Group 
Nick Hurst 300 5th Ave. SW, 10th Floor Calgary, Alberta T2P 3C4 Tel: 
403.218.2835 Fax: 403.218.2830 nhurst@equicomgroup.com  Dian Griesel, Inc. 
Susan Forman 396 West Broadway, 2nd Floor New York, NY 10012 Tel: 
212.825.3210 Fax: 212.825.3229 sforman@dgicomm.com 
SOURCE: Oncolytics Biotech Inc. 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/February2013/20/c6935.html 
CO: Oncolytics Biotech Inc.
ST: Alberta
NI: BTC NEWSTK  
-0- Feb/20/2013 14:00 GMT